Fixed-duration ibrutinib plus venetoclax provides an overall survival advantage and better sustained progression-free survival regardless of measurable residual disease (MRD) status compared with chlorambucil plus obinutuzumab as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).